Pasar al contenido principal

Ariadna Laguna Tuset

I am a neuroscientist with extensive experience in the molecular mechanisms underlying both neurodevelopmental and neurodegenerative diseases of the nervous system. My current research is aimed at identifying new therapeutic targets and biomarkers to improve the diagnosis and treatment of Parkinson's disease.

Instituciones de las que forman parte

Investigador/a principal
Enfermedades Neurodegenerativas
Vall Hebron Institut de Recerca

Ariadna Laguna Tuset

Instituciones de las que forman parte

Investigador/a principal
Enfermedades Neurodegenerativas
Vall Hebron Institut de Recerca

I am a neuroscientist with extensive experience in the molecular mechanisms underlying both neurodevelopmental and neurodegenerative diseases of the nervous system. My current research is aimed at identifying new therapeutic targets and biomarkers to improve the diagnosis and treatment of Parkinson's disease.

I received my Biology degree, Health and Life Sciences specialization, in 2003 at the Universitat Pompeu Fabra (Barcelona, Spain). I got my Ph.D. in 2008 in the laboratory of Dr. Mariona Arbonés at the Center for Genomic Regulation (CRG, Barcelona, Spain). My Ph.D. was devoted to study the molecular basis of Down Syndrome neurological alterations. In 2009, I joined the group of Professor Thomas Perlmann at the Ludwig Institute for Cancer Research – Karolinska Institutet (Stockholm, Sweden) as a post-doctoral Marie Curie researcher to work on the transcriptional regulation of dopamine neurons during development and in pathological conditions such as Parkinson’s disease.

In 2014, I moved back to Barcelona and joined the Neurodegenerative Diseases Research Group at the Vall d’Hebron Research Institute (VHIR) as a Beatriu de Pinós post-doctoral researcher funded by AGAUR-FP7 Marie Curie Actions. Afterwards, I received a Young Investigator contract from the Spanish government (Ministry of Economy and Competitiveness (MINECO)) and a Junior Leader fellowship from the La Caixa Foundation to establish my own research lines within the group. In addition, I am an associate researcher at the Neuroscience Institute of the Autonomous University of Barcelona (UAB) and Scientific Ambassador of the World Parkinson Coalition.

The research from my team is devoted to elucidate the molecular mechanisms of inter-organ communication in Parkinson’s disease and how this contributes to the pathophysiology and symptoms of this neurodegenerative disorder. Our research contributes to: (i) identify biomarkers for early detection, disease progression or response to treatment, (ii) identify new molecular targets and develop novel therapeutic strategies with disease-modifying potential, (iii) unravel molecular pathways common to other neurodegenerative or metabolic diseases. Researcher ID: F-9561-2016; Orcid: 0000-0002-9732-6677.

Líneas de investigación

Identification of biomarkers of prodromal Parkinson's disease

Despite intensive efforts towards understanding the aetiology/pathogenesis of Parkinson's disease (PD) and the development of novel therapeutic approaches for this neurodegenerative condition, the current treatment for PD remains symptomatic and yet far from modifying disease onset or progression. Before the manifestation of the classical motor symptoms, PD patients present with non-motor symptoms in a prodromal phase. The identification of deregulated molecular pathways or genes in peripheral blood and/or cerebrospinal fluid from these prodromal patients may help develop potential biomarkers for the early detection, diagnosis, risk assessment and/or progression of PD, which are currently lacking, as well as to stratify patients at very early stages to apply more specific, personalized disease-modifying treatments.

IP: Miquel Vila Bover, Ariadna Laguna Tuset

Proyectos

El eje cerebro-cuerpo en la enfermedad de Parkinson: de la fisiopatología a los biomarcadores y enfoques terapéuticos.

IP: Ariadna Laguna Tuset
Colaboradores: Miriam Izquierdo Sans , Laia Perez Lasarte
Entidad financiadora: Ministerio de Ciencia e Innovación-MICINN
Financiación: 236350
Referencia: RYC2021-032947-I
Duración: 01/01/2023 - 31/12/2027

Ministerio de Ciencia

Malalties neurodegeneratives

IP: Miquel Vila Bover
Colaboradores: Jorge Hernández Vara, Joan Compte Barrón, Marta Martínez Vicente, Jordi Bove Badell, Eddie Pradas Gracia, Maria Camprodon Gomez, Núria Peñuelas Peñarroya, Camille Guillard Sirieix, Marina Lorente Picón, Laura Castillo Ribelles, Oriol de Fabregues-Boixar Nebot, Javier Hoyo Pérez, Ariadna Laguna Tuset, Thais Cuadros Arasa, Jordi Riera Heredia, David Ramos Vicente, Marta Montpeyó Garcia-Moreno, Maria Sellés Altés, Helena Xicoy Cortada, Alba Nicolau Vera, Marta González Sepúlveda, Anna Garcia Serra, Joana Margalida Cladera Sastre, Annabelle Parent , Daniela Samaniego Toro, Daniela Samaniego Toro
Entidad financiadora: AGAUR no fer servir-correcte 4301-37
Financiación: 40000
Referencia: 2021 SGR 00784
Duración: 01/01/2022 - 31/12/2024

Peripheral synucleinopathy: pathogenicity and modulation of propagation

IP: Ariadna Laguna Tuset
Colaboradores: -
Entidad financiadora: Parkinson's Foundation
Financiación: 54466.62
Referencia: PARKINSON.F_IMPACT2022
Duración: 01/07/2022 - 31/05/2024

Activity and connectivity drive neuronal vulnerability and disease progression in Parkinson's disease

IP: Miquel Vila Bover
Colaboradores: Joan Compte Barrón, Javier Hoyo Pérez, Gerard Roch Alba, Marta González Sepúlveda, Ariadna Laguna Tuset, Joana Margalida Cladera Sastre, Núria Peñuelas Peñarroya
Entidad financiadora: Michael J. Fox Foundation
Financiación: 1269495.05
Referencia: ASAP_MJFF2021
Duración: 01/11/2021 - 31/10/2024

Noticias relacionadas

El Dr. Miquel Vila, jefe del grupo de investigación en Enfermedades Neurodegenerativas del VHIR, es el copresidente del comité organizador local. Y la Dra. Ariadna Laguna, investigadora principal del mismo grupo, es embajadora científica.

Los Premios Best in Class reconocen los mejores servicios y unidades del Estado, tanto públicos como privados, que buscan la excelencia en la atención que prestan a sus pacientes.

La segunda edición de la Jornada de Parkinson ha permitido compartir conocimientos y experiencias centrados en la terapia más allá de la levodopa, considerada la estándar para mejorar los síntomas motores de los pacientes.

Profesionales relacionados

Joseane Willamil Dos Santos

Joseane Willamil Dos Santos

Tècnic/a Superior Recerca
Unidad de Cirugía Experimental (ESU)
Core Facilities Preclínicos
Área de Core Facilities
Leer más
Anna Pedrol Clara

Anna Pedrol Clara

Administrativo/va
Servicios Generales e Infraestructura
Gerencia
Leer más
Jennifer Ana Pérez Castro

Jennifer Ana Pérez Castro

Investigador postdoctoral
Sistema Nervioso Periférico
Leer más
Mª Helena Galilea Casellas

Mª Helena Galilea Casellas

Administrativo/va
Unidad de Apoyo a los Comités de Ética (USCE)
Área de Core Facilities
Leer más

Suscríbete a nuestros boletines y forma parte de la vida del Campus

Vall d'Hebron Barcelona Hospital Campus es un parque de referencia mundial donde la asistencia, la investigación, la docencia y la innovación se dan la mano.